170 related articles for article (PubMed ID: 35759904)
21. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
Maarouf A; Rico A; Boutiere C; Perriguey M; Demortiere S; Pelletier J; Audoin B;
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32587103
[TBL] [Abstract][Full Text] [Related]
22. Depression, anxiety, and fear of COVID-19 in patients with multiple sclerosis in pandemic era: a cross-sectional study.
Alirezaei M; Eskandarieh S; Sahraian MA; Naser Moghadasi A
Neurol Sci; 2022 Jan; 43(1):59-66. PubMed ID: 34554334
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
24. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
25. Natural history of relapsing remitting multiple sclerosis in a long-lasting cohort from a tertiary MS centre in Portugal.
Sá MJ; Sequeira L; Ferro D; Marcolino A; Rocha AL; Seabra M; Mendonça T; Abreu P; Guimarães J; Macedo A
Mult Scler Relat Disord; 2021 Sep; 54():103091. PubMed ID: 34246020
[TBL] [Abstract][Full Text] [Related]
26. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
[TBL] [Abstract][Full Text] [Related]
27. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
28. A case series and literature review of multiple sclerosis and COVID-19: Clinical characteristics, outcomes and a brief review of immunotherapies.
Kataria S; Tandon M; Melnic V; Sriwastava S
eNeurologicalSci; 2020 Dec; 21():100287. PubMed ID: 33163634
[TBL] [Abstract][Full Text] [Related]
29. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
30. Impact of COVID-19 on prescribing patterns and treatment selection of disease modifying therapies in multiple sclerosis.
Zaheer R; Amin R; Riddick L; Roy S; Wolff S; Nathanson A; Newsome S
Mult Scler Relat Disord; 2023 Mar; 71():104575. PubMed ID: 36857853
[TBL] [Abstract][Full Text] [Related]
31. Predictors of severity and outcome of multiple sclerosis relapses.
Hosny HS; Shehata HS; Ahmed S; Ramadan I; Abdo SS; Fouad AM
BMC Neurol; 2023 Feb; 23(1):67. PubMed ID: 36782141
[TBL] [Abstract][Full Text] [Related]
32. Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.
Jakimovski D; Kavak KS; Vaughn CB; Goodman AD; Coyle PK; Krupp L; Gottesman M; Edwards KR; Lenihan M; Perel A; Zivadinov R; Weinstock-Guttman B;
Mult Scler Relat Disord; 2022 Jan; 57():103406. PubMed ID: 34915316
[TBL] [Abstract][Full Text] [Related]
33. No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.
Zafar A; AlShamrani FJG
Mult Scler Relat Disord; 2021 Jun; 51():102875. PubMed ID: 33691260
[TBL] [Abstract][Full Text] [Related]
34. Registry of patients with multiple sclerosis and COVID-19 infection in Saudi Arabia.
Alshamrani F; Alnajashi H; AlJumah M; Almuaigel M; Almalik Y; Makkawi S; Alsalman S; Almejally M; Qureshi S; Aljarallah S; AlKhawajah N; Kedah H; Alotaibi H; Saeedi J; Alamri A
Mult Scler Relat Disord; 2021 Jul; 52():103004. PubMed ID: 34049217
[TBL] [Abstract][Full Text] [Related]
35. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
36. COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?
Etemadifar M; Sedaghat N; Aghababaee A; Kargaran PK; Maracy MR; Ganjalikhani-Hakemi M; Rayani M; Abhari AP; Khorvash R; Salari M; Nouri H
Mult Scler Relat Disord; 2021 Jun; 51():102915. PubMed ID: 33799284
[TBL] [Abstract][Full Text] [Related]
37. COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.
Luetic G; Menichini ML; Burgos M; Alonso R; Carnero Contentti E; Carrá A; Deri N; Steinberg J; Rojas JI;
Mult Scler Relat Disord; 2021 Aug; 53():103049. PubMed ID: 34130197
[TBL] [Abstract][Full Text] [Related]
38. Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
Algahtani H; Shirah B; Al Malik Y; Meftah I
Clin Neuropharmacol; 2020; 43(2):35-38. PubMed ID: 32106137
[TBL] [Abstract][Full Text] [Related]
39. Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.
Rolfes L; Pawlitzki M; Pfeuffer S; Nelke C; Lux A; Pul R; Kleinschnitz C; Kleinschnitz K; Rogall R; Pape K; Bittner S; Zipp F; Warnke C; Goereci Y; Schroeter M; Ingwersen J; Aktas O; Klotz L; Ruck T; Wiendl H; Meuth SG
Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34261812
[TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population.
Hadidchi R; Wang SH; Rezko D; Henry S; Coyle PK; Duong TQ
Mult Scler Relat Disord; 2024 Jun; 86():105613. PubMed ID: 38608516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
